Silver complexes of ligands derived from adamantylamines : water-soluble silver-donating compounds with antibacterial properties

Jorge Jimenez, Indranil Chakraborty, Mauricio Rojas-Andrade, Pradip K. Mascharak*

*Department of Chemistry and Biochemistry, University of California, Santa Cruz, CA
95064, USA*

Tel: +1 831 459 4251

fAX: +1 831 459 2935

E-mail address: Pradip@ucsc.edu (P. K. Mascharak)

Keywords: Antibacterial, Silver complex, Water soluble, Triazaadamantane moiety,
Schiff base ligands

ABSTRACT

Two new silver(I) complexes, namely $[\text{Ag}(\text{qyAm})_2](\text{CF}_3\text{SO}_3)$ (**1**) and $[\text{Ag}(\text{qyTAm})_2](\text{CF}_3\text{SO}_3)$ (**2**), (qyAm = 2-(quinonyl)iminoadamantane, qyTAm = 2-(quinonyl)iminotriazaadamantane) have been synthesized and characterized by elemental analyses, ^1H NMR, IR, electronic absorption spectroscopy, and X-ray diffraction. The coordination geometry of the silver center in both complexes is distorted tetrahedral where their respective qyAm and qyTAm ligand bind in a bidentate fashion using the imine and quinoline nitrogen atoms. Complex **2** is soluble in water and exhibits strong antimicrobial actions on both Gram-negative (*E. coli*, and *P. aeruginosa*) and Gram-positive (*S. aureus*) bacteria. The MIC values for complex **2** (4, 4, and 8 μg for *E. coli*, *P. aeruginosa*, and *S. aureus*, respectively) are comparable to MIC values of silver nitrate and silver sulfadiazine.

1. Introduction

Antimicrobial resistance has emerged as an increasing problem among developed nations in the hospital settings [1]. Antibacterial drugs that were once effective against different pathogens are no longer effective in eradication of bacterial infections. *Pseudomonas aeruginosa*, a Gram-negative bacteria, rarely causes infection in healthy people and yet is one of the major causes of death in hospitalized patients [2]. *P. aeruginosa* often becomes multi-drug resistant due to indiscriminate overuse of antimicrobial drugs and consequently has become more difficult to treat over the past few decades [3]. Similarly *Staphylococcus aureus*, an opportunistic Gram-positive pathogen often encountered in the medical settings, has acquired resistance to methicillin-derived antibiotics and is notoriously difficult to treat [3]. Both *P. aeruginosa* and *S. aureus* cause life-threatening infection in patients with severe burn-wounds which results from delay in the wound healing process due to bacterial colonization [4]. Bacterial colonization in wounds is often polymicrobial and hence broad-spectrum antibiotics are the best options

for treatment. As a consequence, novel broad-spectrum antimicrobials for effective treatment of infections in wound burns are of paramount importance.

Silver has been known to possess antimicrobial properties for more than two thousand years and is considered a broad-spectrum antimicrobial agent [5]. Pharmaceutical application of silver was first recognized with the use of silver nitrate (AgNO_3) in early 1800s for the treatment of ulcers [6]. The discovery of penicillin and its potent antibacterial properties led to a diminution of interest in silver and it was not until the 1960s when use of silver was reintroduced in the form of 0.5% AgNO_3 solution to treat wounds on burn victims [6,7]. In addition, silver has been utilized in creams for topical treatment of burns and wounds in the form of silver sulfadiazine (AgSD). AgSD exhibits high efficacy in eradication of *P. aeruginosa* with minimum side effects in the wound healing process compared to AgNO_3 [7].

It is well established that metallic silver causes minimum damage to living organism and cationic Ag^+ is the biologically active species in applications of silver-containing compounds and formulations [5]. The antimicrobial properties of Ag^+ are mainly attributed to its ability to bind thiols on proteins and enzymes [5], block cellular respiration [5], cause cell membrane damage [5], and bind to nucleic acids [8]. In addition to silver salts, silver complexes derived from various ligands have regained attention as antimicrobial agents [9]. Research in this area has indicated that the choice of ligand is of crucial importance in the development of antimicrobial silver complexes. Ideally, the ligands coordinated to silver should provide some desired physical, chemical, and/or biological properties that ultimately result in antimicrobial activity superior to that of pure silver salts. Although a number of silver complexes have been developed toward this goal, their biological use is often limited due to poor water solubility as in the case of AgSD [10].

Recently, we have been interested in the design and synthesis of ligands that could impart enhanced solubility of their silver complexes and rapid accumulation inside bacteria. In particular, we focused on the adamantyl moiety (Figure 1a) which is lipophilic and has been shown to facilitate the process of cellular uptake of the compounds into which it is incorporated [11]. To date the adamantyl functionality has been widely utilized in the pharmaceutical industry including in many antiviral,

antimicrobial and anticancer drugs used worldwide [11,12]. 1-adamantylamine, shown in Figure 1c, is a derivative of adamantane that also possesses medicinal properties. Following this lead we first synthesized the Schiff base ligand 2-(quinonyl)iminoadamantane (qyAm) and the silver complex $[\text{Ag}(\text{qyAm})_2](\text{CF}_3\text{SO}_3)$ (**1**) derived from it. The limited solubility of complex **1** in water however forced us to look for a better alternative. A scrutiny of the literature revealed that 1,3,5-triaza-7-phosphaadamantane (PTA, Figure 1b) has been widely utilized in the synthesis of metal complexes with excellent cellular uptake properties [13,14]. In addition, PTA is water-soluble, and metal complexes derived from it also show high solubility in aqueous media. Such complexes have been reported to possess anticancer properties [15-19]. Therefore in our next attempt we incorporated 1,3,5-triazaadamant-7-amine (Figure 1d), a derivative of PTA, in the Schiff base frame and isolated 2-(quinonyl)iminotriazaadamantane (qyTAm). This water-soluble ligand afforded complex $[\text{Ag}(\text{qyTAm})_2](\text{CF}_3\text{SO}_3)$ (**2**) which exhibits significant solubility in aqueous media. Herein we report the syntheses, structures, and spectral characterization of the two complexes. In addition, the antibacterial properties of complex **2** have been assessed against both Gram-negative (*Escherichia coli* and *P. aeruginosa*) and Gram-positive (*S. aureus*) bacteria and their antimicrobial efficacies compared to that of silver nitrate and AgSD.

Figure 1. Structures of adamantane (**a**), 1,3,5-triaza-7-phosphaadamantane (PTA, **b**), 1-adamantylamine (**c**) and 1,3,5-triazaadamant-7-amine (**d**)

2. Experimental

2.1. Materials and Methods

All reagents were of commercial grade and were used without further purification. The solvents were purified according to a standard procedure [20]. Quinoline-2-carboxaldehyde, silver trifluoromethanesulfonate and silver nitrate were purchased from Sigma Aldrich. 1-adamantylamine was purchased from Alpha Aesar. 1,3,5-triazaadamant-7-amine was purchased from MolPort. A PerkinElmer Spectrum-One FT-IR spectrometer was employed to obtain the IR spectra of the compounds. UV-Vis spectra were recorded on a Varian Cary 50 UV-Vis spectrophotometer. ^1H NMR spectra at 298 K were monitored on a Varian Unity Inova 500 MHz instrument. Microanalyses (C, H, N) were performed using a Perkin-Elmer 2400 Series II elemental analyzer.

2.2. Synthesis of ligands.

2.2.1. 2-(quinonyl)iminoadamantane (qyAm): Quinoline-2-carboxaldehyde 519.6 mg (3.3 mmol) and 1-adamantylamine 500 mg (3.3 mmol) were added to 35 mL of dry methanol and allowed to stir at room temperature for 18 h. The color of the solution changed from clear to pale-yellow within 30 min. After 18 h the volume of the solution was reduced to 5 mL and 15 mL of diethyl ether was added to it. The white solid thus separated was filtered and washed with cold methanol (yield: 777 mg, 81.2 %). Anal. Calcd. for $\text{C}_{20}\text{H}_{22}\text{N}_2$: C, 82.74; H, 7.67; N, 9.68. Found: C, 82.71; H, 7.65; N, 9.58. (KBr, cm^{-1}): 2907 s, 2844 s, 1633 w, 1595 m, 1557 w, 1500 m, 1449 w, 1429 w, 1343 w, 1304 m, 1116 w, 1087 m, 890 w, 843 m, 753 s. ^1H NMR (CDCl_3 , δ from TMS): 8.51 (s, 1H), 8.19 (d, 1H), 8.14 (d, 1H), 8.09 (d, 1H), 7.80 (d, 1H), 7.71 (t, 1H), 7.54 (t, 1H), 2.18 (s, 4H), 1.86 (s, 6H), 1.71 (d, 5H). ^{13}C NMR (CDCl_3 , δ from TMS): 156.62, 155.88, 147.68, 136.31, 129.56, 129.35, 128.64, 127.62, 127.02, 118.18, 58.38, 42.97, 36.47, 29.47.

2.2.2. 2-(quinonyl)iminotriazaadamante (qyTAM) was synthesized by following a procedure reported by us in a previous account [21]. The yield of the ligand (white solid) was 668 mg (68.8 %). Anal. Calcd. for $\text{C}_{17}\text{H}_{19}\text{N}_5$: C, 69.64; H, 6.58; N, 23.92. Found: C, 69.60; H, 6.55; N, 23.87. IR (KBr, cm^{-1}): 2930 m, 2910 m, 2860 m, 1710 w, 1637 w, 1596 w, 1501 w, 1447 w, 1363 w, 1295 w, 1241 m, 1218 w, 1111 w, 1027 s, 993 s, 835 m, 821 s, 792 w, 751 m, 638 m. ^1H NMR (CDCl_3 , δ from TMS): 8.43 (s, 1H), 8.15 (m,

2H), 8.09 (d, 1H), 7.82 (d, 1H), 7.73 (t, 1H), 4.52 (d, 3H), 4.15 (d, 3H), 3.54 (s, 6H). ^{13}C NMR (CDCl_3 , δ from TMS): 160.27, 155.22, 137.04, 130.36, 129.94, 128.18, 128.00, 118.19, 74.06, 62.62.

2.3. Synthesis of complexes

2.3.1. $[\text{Ag}(\text{qyAM})_2](\text{CF}_3\text{SO}_3)$ (**1**). To a solution of 200 mg (0.779 mmol) of AgCF_3SO_3 in 15 mL in dry methanol, a batch of 263 mg (0.1559 mmol) of qyAM in 10 mL of dry methanol was added and the mixture was allowed to stir for 18 h at room temperature. Next, the volume of the reaction mixture was reduced to 10 mL and 15 mL of diethyl ether was added. The white precipitate thus obtained was filtered, washed with cold methanol and dried in *vacuo* (yield: 470 mg, 72%). X-ray quality crystals were obtained by layering hexanes over solution of the complex in dichloromethane. Anal. Calcd. for $\text{C}_{41}\text{H}_{44}\text{N}_4\text{O}_3\text{F}_3\text{SAg}$: C, 58.84; H, 5.32; N, 6.72. Found: C, 58.89; H, 5.29; N, 6.76. IR (KBr, cm^{-1}): 2905 s, 2848 s, 645 w, 1592 w, 1508 m, 1453 w, 1431 w, 1343 w, 1307 m, 1263 s, 1223 m, 1154 s, 1031 s, 994 w, 934 w, 829, m, 757 m, 636 s, 572 w, 517 w. ^1H NMR (CDCl_3): 8.90 (s, 1H), 8.58 (d, 1H), 8.11 (d, 1H), 7.92 (d, 1H), 7.73 (d, 1H), 7.60 (t, 1H), 7.56 (t, 1H). 2.13 (s, 3H), 1.91 (s, 6H), 1.67 (d, 4H), 1.59 (d, 2H).

2.3.2. $[\text{Ag}(\text{qyTAM})_2](\text{CF}_3\text{SO}_3)$ (**2**). A batch of 460 mg 1.558 (mmol) of qyTAM in 10 mL of dry methanol was added to a solution of 200 mg (0.779 mmol) of AgCF_3SO_3 in 15 mL of dry methanol and the mixture was allowed to stir for 24 h at room temperature. Next, the volume of the pale yellow solution was reduced to 10 mL and 10 mL of diethyl ether was added. The white solid thus precipitated was filtered and dried in *vacuo*. X-ray quality crystals were obtained by slow evaporation of a solution of the complex in methanol. Yield: 468 mg (71%). Anal. Calcd. for $\text{C}_{35}\text{H}_{38}\text{N}_{10}\text{O}_3\text{F}_3\text{SAg}$: C, 49.85; H, 4.58; N, 16.65. Found: C, 49.87; H, 4.53; N, 16.60. IR (KBr, cm^{-1}) 2904 s, 2848 s, 1645 w, 1591 w, 1507 m, 1452 w, 1430 w, 1343 w, 1307 m, 1262 s, 1223 s, 1153 s, 1087 m, 1031 s, 994 w, 933 w, 828 m, 757 m 636 s, 571 w, 516 w. ^1H NMR (CDCl_3): 8.52 (s, 1H), 8.24 (d, 1H), 8.15 (d, 1H), 8.08 (d, 1H), 7.86 (d, 1H), 7.75 (t, 1H), 7.60 (t, 1H). 4.53 (s, 3H), 4.17 (s, 3H), 3.57 (d, 6H).

2.4. X-ray data collection and structure refinement

One suitable crystal from each sample vial was mounted on MitiGen loop with Paratone-N oil (Hampton Research) and transferred to the diffractometer. Data were collected on Bruker single crystal X-ray diffractometer equipped with PHOTON 100 and APEX II detector for complex **1** and **2** respectively. For complex **1** the data were collected with synchrotron radiation source by the ϕ and ω -scan technique in the range $3 \leq 2\theta \leq 79$ (Table 1) while for complex **2** sealed tube Mo source was employed and the data were collected by ω -scan technique in the range $3 \leq 2\theta \leq 50$ (Table 1). Data integration and reduction were performed with SAINT module [22]. The multi scan semi-empirical absorption correction was applied to the collected reflections using SADABS for both cases. The structures were generated using ShelXT (intrinsic phasing) [23] using Olex2 [24] graphical user interface and subsequently refined by full-matrix least squares procedure on F^2 using ShelXL refinement package [25]. For both structures appropriate SHELX compatible constraints and restraints were applied to model some atoms with relatively higher anisotropic displacement parameters. All hydrogen atoms were included in calculated positions on the C atoms to which they are bonded, with C–H = 0.93 Å and $U_{\text{iso}}(\text{H}) = 1.2U_{\text{eq}}(\text{C})$. Calculations were also performed using the SHELXTL 2014 program package [26].

Table 1 Crystal data and structure refinement parameters for **1** and **2**

	1	2
Empirical formula	C ₄₁ H ₄₄ N ₄ O ₃ F ₃ SAg	C ₃₅ H ₃₈ N ₁₀ O ₃ F ₃ SAg
FW	837.73	843.68
Temp (K)	150	298
Crystal System	Monoclinic	Monoclinic
Space group	P2(1)/n	P2(1)/n
a (Å)	18.9803(7)	19.2289(7)
b (Å)	18.6631(7)	18.6472(6)

c (Å)	22.8795(8)	23.2634(8)
α (°)	90	90
β (°)	112.823(2)	112.7390(10)
γ (°)	90	90
V (Å ³)	7470.1(5)	7693.1(5)
Z	8	8
Density (calcd)	1.490	1.457
(g cm ⁻³)		
Abs coeff (mm ⁻¹)	0.814	0.641
No. of unique reflns	34412 (R _{int} = 0.0425)	12764 (R _{int} = 0.0193)
R ₁ ^b (I > 2σ(I))	0.0397	0.0902
wR ₂ ^c	0.1021	0.2651
GOF ^a on F ²	1.021	1.037

^aGOF = $[\Sigma[w(F_o^2 - F_c^2)^2]/(N_o - N_v)]^{1/2}$ (N_o = number of observations, N_v = number of variables). ^bR₁ = $\Sigma||F_o| - |F_c||/\Sigma|F_o|$. ^cwR₂ = $[(\Sigma w(F_o^2 - F_c^2)^2/\Sigma|F_o|^2)]^{1/2}$

2.5. Antibacterial Studies

The bacterial growth kinetics experiments were performed by following procedures reported by Chen and coworkers with a few modifications [27]. Briefly, the bacteria were first grown by spreading frozen liquid culture on a Luria Broth (LB) agar plate and incubating it at 37 °C for 18 h. Next, a single colony was isolated from this plate and used to inoculate 3 mL of LB. The bacterial culture was incubated for 18 h at 37 °C under constant shaking at 250 rpm. A 1 mL aliquot of this bacterial culture was then centrifuged at 5000 rpm for 5 min. The pellet thus obtained was re-suspended in sterile nano-pure water. This process was repeated once more and finally the pellet was added to a 5 mL volume of nano-pure water to obtain a new cell suspension having an absorbance of 0.1 at 600 nm. A 96-well plate was utilized to perform all growth experiments in triplicates, where the final volume of each well was 200 µL. The constituents consisted of 20 µL of the bacterial suspension ($A_{600} = 0.1$), 30 µL of sterile

LB, varying amounts of solutions of the compounds (100, 80, 60, 40, 20, 10, 5, and 0 μL) and the corresponding amount of water required to bring the final volume to 200 μL . Upon inoculation and addition of the complexes, the plate was immediately placed in a plate reader at 37 $^{\circ}\text{C}$ where the optical density was measured at 600 nm for each independent well every minute for 24 h with 10 sec mixing periods between reads.

3. Results and Discussion

3.1. Synthesis and spectral properties of **1** and **2**

Reactions of qyAm and qyTAM with AgCF_3SO_3 in dry methanol afforded Ag(I) complexes **1** and **2** respectively as white crystalline solids. As evident from their structures (shown in Figure 2a and 2b), both ligands bind to the Ag(I) center in a bidentate fashion utilizing the N donor atom of the quinoline ring and the imine N atom. Such coordination causes red shift of the absorption band maximum from 290 nm (in qyAm) to 325 nm in case of complex **1** in dichloromethane and from 303nm (in qyTAM) to 330 nm in case of complex **2** in pure water. In addition, the ^1H chemical shift values for complex **1** and **2** show notable differences in peak positions as compared to the free ligands further indicating coordination of the ligand. In case of complex **1** the proton from the imine functionality appears downfield (δ 8.90 ppm) as compared to the proton from the imine in the free ligand qyAm (δ 8.51 ppm). With complex **2**, the proton from the imine functionality also appears down field (δ 8.52 ppm) as compared to the proton from the imine of the free ligand qyTAM (δ 8.43 ppm).

3.2. Structures of **1** and **2**

The molecular structures of complexes **1** and **2** were authenticated by single crystal X-ray crystallography and are shown in Figure 2. Crystal data collection parameters are listed in Table 1 while selected metric parameters are presented in Table 2. Both complexes crystallize in monoclinic $P2(1)/n$ space group with two crystallographically independent molecules in the asymmetric units. The coordination geometry around Ag is distorted

Figure 2. Molecular structures of the cations of (a) complex **1** and (b) complex **2**. The thermal ellipsoids are drawn at 50% probability level. The hydrogen atoms and the counter anions are omitted for the sake of clarity.

tetrahedral. In **1** both chelate rings (constituted by Ag1 N1, C9, C10, N2 and Ag1, N3, C29, C30, N4 atoms) are reasonably planar with mean deviations of 0.033 and 0.039 Å respectively. The corresponding planes in complex **2** exhibit similar trend (mean deviations 0.027 and 0.028 Å). The dihedral angles between the two chelate planes for complexes **1** and **2** are 80.4 and 78.3° respectively. In each case, the average Ag–N distance (2.328 and 2.327 Å for **1** and **2** respectively) is quite similar for the two cations within the asymmetric unit. Distorted tetrahedron coordination geometry is not uncommon for Ag complexes with N donor ligands. A similar Ag complex with N donor namely, $[\text{Ag}(\text{bpy-OH})_2]^+$ (where bpy-OH = bis(hydroxymethyl)-2,2'-bipyridne) exhibits distorted tetrahedral geometry with average Ag–N distance of 2.320 Å [28] comparable to that observed for the present complexes. No noticeable π - π stacking or other intermolecular interactions are realized upon careful examination of the crystal packing for both the structures.

Table 2. Selected bond distances (Å) and angles (°) for complexes **1** and **2**

	Complex 1		Complex 2	
	Molecule 1	Molecule 2	Molecule 1	Molecule 2
Ag1–N1	2.3501(11)	–	2.355(5)	–
Ag1–N2	2.3183(12)	–	2.308(5)	–
Ag1–N3	2.3541(12)	–	2.359(5)	–
Ag1–N4	2.3156(11)	–	2.305(6)	–
Ag2–N5	–	2.3265(11)	–	2.317(6)
Ag2–N6	–	2.3224(12)	–	2.326(5)
Ag2–N7	–	2.3155(11)	–	2.324(6)
Ag2–N8	–	2.3196(11)	–	2.322(6)
N1–Ag1–N2	72.27(4)	–	72.44(18)	–
N1–Ag1–N4	139.16(4)	–	131.0(2)	–
N2–Ag1–N3	130.07(4)	–	138.6(2)	–
N1–Ag1–N3	119.34(4)	–	115.30(19)	–
N4–Ag1–N2	132.79(4)	–	135.4(2)	–
N4–Ag1–N3	72.66(4)	–	72.5(2)	–
N7–Ag2–N8	–	72.60(4)		72.9(2)
N7–Ag2–N5	–	130.73(4)		131.3(2)
N8–Ag2–N5	–	123.73(4)		134.7(2)
N7–Ag2–N6	–	136.75(4)		126.2(2)
N8–Ag2–N6	–	129.55(4)		129.1(2)
N5–Ag2–N6	–	72.82(4)		72.5(2)

3.3. Solubility in aqueous media

Rapid precipitation (as AgCl) in biological media often poses as a problem in the treatment of burn wounds with AgNO₃. Such precipitation renders the bioactive Ag⁺ ions unavailable at the wound bed. Because effective treatment of infections requires sustained release of Ag⁺, researchers have attempted use of different silver complexes to resist the rapid exit of the bioactive “drug” from the interaction zone [19,28,29]. In the present study only **2** exhibits solubility in water (1mg/mL) and we have carefully measured the stability of **2** in water at 37 °C. As shown in Figure S1 (Supporting Information), complex **2** slowly releases Ag⁺ in such solution. Periodic checking of the absorption spectrum of a solution of **2** in water reveals that the spectrum slowly transitions to the spectrum of the ligand over a period of 2 h. This observation confirms the fact that **2** is an effective silver-donating complex that ensures slow release of Ag⁺ when applied to infected wounds. It is important to note that constant exposure of such solutions to visible light does not expedite the rate of silver release (as monitored by absorption spectroscopy), a fact that confirms the stability of the complex towards light.

3.4. Antibacterial Studies

Antibacterial activities of both complexes have been assessed in the present study against two Gram-negative (*E. coli* and *P. aeruginosa*) and one Gram-positive (*S. aureus*) bacteria. The ligands by themselves display no antimicrobial activity against any of the three bacteria up to a concentration of 100 µM. While complex **1** exhibits limited solubility in water, complex **2** is readily soluble in water and several bacterial growth media. This allowed us to determine the minimal inhibitory concentration (MIC) of complex **2**. MIC is defined as the lowest concentration of the compound able to inhibit the growth of the microorganism. In case of *E. coli*, **2** exhibited a MIC value of 2 µM, a value comparable to AgNO₃ (2 µM) as well as AgSD (4 µM). As previously stated, both AgNO₃ and AgSD are regularly utilized in Burn Victim Wards of hospitals for wound healing purposes. The bacterial growth curves for *P. aeruginosa* with increasing concentration of **2** are shown in Figure 3. With this Gram-negative pathogen **2** exhibited a slightly higher MIC value of 4 µM. The corresponding MIC values for AgNO₃ and AgSD were 4 µM and 8 µM, respectively. A somewhat higher MIC value (8 µM) was

Figure 3. Bacterial growth curves for *P. aeruginosa* in presence of complex **2** (a), AgNO_3 (b), and AgSD (c). The y-axis absorbance is directly proportional to bacterial population.

obtained for **2** against the Gram-positive bacterium *S. aureus*. Incidentally, higher MIC values were also noted for both AgNO₃ (6 μM) and AgSD (8 μM) against this nosocomial pathogen. These higher MIC values most possibly arise from differences in cell membrane structure and compositions of the Gram-positive and Gram-negative bacteria employed in this study [30]. Bacterial growth curves for both *E. coli* and *S. aureus* are included in Supplementary Information.

Table 3. MIC values of the different silver salts and complex **2**

	<i>E. coli</i>	<i>P. aeruginosa</i>	<i>S. aureus</i>
Compound	MIC (μM)	MIC (μM)	MIC (μM)
AgNO ₃	2	4	6
AgSD	4	8	8
2	4	4	8

To date the antimicrobial and antifungal effects of a few silver complexes have been reported. In a recent report, Smolenski et al. have described the antimicrobial activity of a highly light-stable and water-soluble silver complex derived from N-methyl-1,3,5-triaza-7-phosphaadamantane (mPTA) against both Gram-positive and Gram-negative bacteria [30]. Polymeric complexes with silver-organic network with bridging PTA ligands also exhibit solubility in water and significant antibacterial and antifungal activity [31]. Interesting antimicrobial behavior has been noted with a silver(I) nicotinate cluster [Ag(Hmna)₆] and its anionic form [Ag(mna)]₆⁶⁻ (H₂mna = 2-mercaptonicotinic acid) where the neutral complex have shown activity against both Gram-positive and Gram-negative bacteria while the anionic complex exhibited activity only against Gram-negative bacteria [32]. The difference has been attributed to solubility, transport phenomena, and ligand exchange equilibria. Along the same line, a neutral and water-soluble complex of silver(I) with L-histidine namely [Ag(Hhis)], exhibits a wide spectrum of antibacterial and antifungal activity [33]. It is generally believed that facile

ligand replacement by biological ligands in silver(I)-N bonding compounds is a key factor that leads to wide spectrum of antimicrobial activity [34]. The solubility properties and unusually strong antibacterial activity (Table 2) of the present complex **2** with silver(I)-N bonding appears to support this hypothesis. Although the ligand qyTAm itself does not exhibit significant antibacterial properties, the presence of triazaadamantyl moiety in the ligand frame facilitates increased cellular uptake of **2** and increases its solubility in aqueous media. Taken together, the strong antibacterial activity of complex **2** demonstrates the relationship between solubility and structure/activity of silver(I) complexes which can be further explored toward isolation of more effective silver-containing pharmaceuticals to thwart wound infections.

4. Conclusions

In conclusion two Ag(I) complexes **1** and **2**, derived from designed Schiff base ligands, have been synthesized and structurally characterized. Complex **2** is readily soluble in water and releases Ag⁺ slowly in such solution. This property of **2** has been exploited to eradicate Gram-negative and Gram-positive bacteria. The MIC values of **2** against both classes of pathogen are very comparable to AgNO₃ and AgSD. The slow release of Ag⁺ from **2** in water could be an advantage in keeping the silver donor more in circulation (compared to AgNO₃) and avoid frequent dressing of infected burn wounds to remove the precipitated AgNO₃.

Abbreviations

AgSD	Silver sulfadiazine
PTA	1,3,5-triaza-7-phosphaadamantane
mPTA	N-methyl-1,3,5-triaza-7-phosphaadamantane
qyAm	2-(quinonyl)iminoadamantane
qyTAm	2-(quinonyl)iminotriazaadamantane
LB	Luria Broth
MIC	Minimal inhibitory concentration

H ₂ mna	2-mercaptonicotinic acid
Hhis	L-histidine

Acknowledgments

Financial support from the NSF grant DMR-1409335 is gratefully acknowledged. JJ was supported by the NIH grant 2R25GM058903. The Advanced Light Source is supported by the Director, Office of Basic Energy Sciences of the U. S. Department of Energy under Contract No. DE-AC02-05CH11231.

References

- [1] R.N. Jones, Am. J. Med. 100 (1996) 3S-12S.
- [2] J.A. Korvick, V.L. Yu, Antimicrob. Agents Chemother. 35 (1991) 2167-2172.
- [3] R.N. Jones, M.A. Pfaller, Diagn. Microbiol. Infec. Dis. 31 (1998) 379-388.
- [4] P.G. Bowler, B.I. Duerden, D.G. Armstrong, Clin. Microbiol. Rev. 14 (2001) 244-269.
- [5] J. Fong, F. Wood, Int. J. Nanomedicine 1 (2006) 441-449.
- [6] I. Chopra, J. Antimicrob. Chemother. 59 (2007) 587-590.
- [7] H.J. Klasen, Burns 26 (2000) 131-138.
- [8] R.H. Jensen, N. Davidson, Biopolymers 4 (1966) 17-32.
- [9] I.M. Azocar, G. Gomez, P. Levin, M. Paez, H. Muñoz, N. Dinamarca, J. Coord. Chem. 67 (2014) 3840-3853.
- [10] M. Rai, A. Yadav, A. Gade, Biotechnol. Adv. 27 (2009) 76-83.
- [11] G. Lamoureux, G. Artavia, Curr. Med. Chem. 17 (2010) 2967-2978.
- [12] L. Wanka, K. Iqbal, P.R. Schreiner, Chem. Rev. 113 (2013) 3516-3604.
- [13] M.V. Babak, S.M. Meier, K.V.M. Huber, J. Reynisson, A.A. Legin, M.A. Jakupec, A. Roller, A. Stukalov, M. Gridling, K.L. Bennett, J. Colinge, W. Berger, P.J. Dyson, G. Superti-Furga, B.K. Keppler, C.G. Hartinger, Chem. Sci. 6 (2015) 2449-2456.

- [14] B.S. Murraya, M.V. Babak, C.G. Hartinger, P.J. Dyson, *Coord. Chem. Rev.* 306 (2016) 86-114.
- [15] C.S. Allardyce, P.J. Dyson, *Dalton Trans.* 45 (2016) 3201-3209.
- [16] R.F.S. Lee, S. Escrig, M. Croisier, S. Clerc-Rosset, G.W. Knott, A. Meibom, C.A. Davey, K. Johnsson, P.J. Dyson, *Chem. Commun.* 51 (2015) 16486-16489.
- [17] K.J. Kilpin, S. Crot, T. Riedel, J.A. Kitchen, P.J. Dyson, *Dalton Trans.* 43 (2014) 1443-1448.
- [18] E. Atrian-Blasco, S. Gascon, M.J. Rodriguez-Yoldi, M. Laguna, E. Cerrada, *Eur. J. Inorg. Chem.* 17 (2016) 2791-2803.
- [19] P. Smolenski, S.W. Jaros, C. Pettinari, G. Lupidi, L. Quassinti, M. Bramucci, L.A. Vitali, D. Petrelli, A. Kochel, A.M. Kirillov, *Dalton Trans.* 42 (2013) 6572-6581.
- [20] W.L.F. Armarego, C.L.L. Chai, In *Purification of Laboratory Chemicals*. Seventh ed. Oxford: Butterworth Heinmann, 2003.
- [21] J. Jimenez, I. Chakraborty, S.J. Carrington, P.K. Mascharak, *Dalton Trans.* 45 (2016) 13204-13213.
- [22] Bruker AXS Inc., Madison, Wisconsin, USA (2015), SAINT-Plus (Version 7.03).
- [23] G.M. Sheldrick, *Acta Cryst.* A71 (2015) 3-8.
- [24] O.V. Dolomanov, L.J. Bourhis, R.J. Gildea, J.A.K. Howard, H. Puschmann, *J. Appl. Cryst.* 42 (2009) 339-341.
- [25] G.M. Sheldrick, *Acta Cryst.* A64 (2008) 112-122.
- [26] G.M. Sheldrick, *Acta Cryst.* C71 (2015) 3-8.
- [27] M. Rojas-Andrade, A.T. Cho, P. Hu, S.J. Lee, C.P. Deming, S.W. Sweeney, C. Saltikov, S. Chen, *J. Mater. Sci.* 50 (2015) 2849-2858.
- [28] T.R. deBoer, I. Chakraborty, M.M. Olmstead, P.K. Mascharak, *Cryst. Growth Des.* 14 (2014) 4901-4905.
- [29] S.W. Jaros, P. Smolenski, M.F.C. Guedes da Silva, M. Florek, J. Krol, Z. Staroniewicz, A.J.L. Pombeiro, A.M. Kirillov, *CrystEngComm.* 15 (2013) 8060-8064.

- [30] P. Smolenski, C. Pettinari, F. Marchetti, M. F. C. Guedes da Silva, G. Lupidi, G. V. B. Patzmay, D. Petrelli, L. A. Vitali, A. J. L. Pombeiro, *Inorg. Chem.* 54 (2015) 434-440.
- [31] S.W. Jaros, M.F.C. Guedes da Silva, M. Florek, M. C. Oliveira, P. Smolenski, A.J.L. Pombeiro, A.M. Kirillov, *Cryst. Growth Des.* 14 (2014) 5408-5417.
- [32] I. Tsyba, B. Bun-kit Mui, R. Bau, R. Noguchi, K. Nomiya, *Inorg. Chem.* 42 (2003) 8028-8032.
- [33] K. Nomiya, S. Takahashi, R. Noguchi, S. Nemoto, T. Takayama, M. Oda, *Inorg. Chem.* 39 (2000) 3301-3311.
- [34] S. Medici, M. Peana, G. Crisponi, V.M. Nurchi, J.I. Lachowicz, M. Remelli, M.A. Zoroddu, *Coord. Chem. Rev.* (2016), DOI: <http://dx.doi.org/10.1016/j.ccr.2016.05.015>.

The silver(I) complex of a Schiff base 2-(quinonyl)iminotriazaadamantane (qyTAm) namely $[\text{Ag}(\text{qyTAm})_2](\text{CF}_3\text{SO}_3)$ (**2**) readily dissolves in aqueous media and causes rapid eradication of both Gram-positive and Gram-negative bacteria with high efficiency. The triazaadamantyl moiety in the ligand frame is responsible for the superior antibacterial activity of this silver complex.